PCA3 and Familial prostate cancer: Differential display analysis of human prostate cancers identified Differential display 3, also known as PCA3, this lncRNA was approved by the Food and Drug Administration (FDA) for prostate cancer diagnosis and was the first case of a lncRNA being used for clinical testing by FDA approval [30, 31].